PPAR Research / 2014 / Article / Fig 1

Research Article

15-Deoxy-γ12,14-prostaglandin J2 Reduces Liver Impairment in a Model of ConA-Induced Acute Hepatic Inflammation by Activation of PPARγ and Reduction in NF-κB Activity

Figure 1

15d-PGJ2 pretreatment group attenuate ConA-induced acute hepatitis. (a) The index of plasma ALT and AST levels at 6 h, 12 h, and 24 h after ConA injection in mice and effects of both low (10 μg) and high (25 μg) dose 15d-PGJ2 pretreatment groups at the same time. Data are expressed as mean ± SD ( , for NC versus ConA, for ConA versus ConA + 10 μg 15d-PGJ2, and for ConA versus ConA + 25 μg 15d-PGJ2). (b) Hematoxylin and eosin staining of liver sections (NC or NC + 10 μg 15d-PGJ2 or NC + 25 μg 15d-PGJ2 or ConA or ConA + 10 μg 15d-PGJ2 or ConA + 25 μg 15d-PGJ2). The cellular necrotic or edematous areas were analyzed with Image-Pro Plus 6.0, indicating there existed statistical significance among different groups ( , for NC versus ConA, for ConA versus ConA + 10 μg 15d-PGJ2, for ConA versus ConA + 25 μg 15d-PGJ2, black bar for 200 μM, wide arrow for necrotic area, and narrow arrow for edematous area).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.